FDA Approves Apalutamide (Erleada); the first treatment for non-metastatic castration-resistant prostate cancer (READ MORE HERE).
Predicting Response to Platinum Chemotherapy in Metastatic..
Mount Sinai School of Medicine, New York
The androgen receptor (AR) is the engine..
Brian Olson, PhD:
University of Wisconsin Carbone Cancer Center
Douglas McNeel, MD, PhD, Glenn Liu, MD
Targeting Resistance to Androgen Deprivation Therapies using Immunotherapies Targeting the Androgen Receptor
BRCA is a gene that mediates DNA..
David Olmos, MBBS, MSc, PhD:
Spanish National Cancer Research Centre
Johann de Bono, MD, PhD, Manuel Hidalgo, MD, PhD
Integration of Clinical, Molecular and Biological Characteristics to Define an Aggressive Subtype of Prostate Cancer Based on Deficient Homologous Recombination